Skip to main content
SpringerLink
Log in

Betarezeptorenblocker

  • Chapter
Arzneiverordnungs-Report 2001

  • 62 Accesses

Zusammenfassung

Betarezeptorenblocker spielen eine wichtige Rolle bei der Behandlung kardiovaskulärer Erkrankungen. Hauptindikationen sind die arterielle Hypertonie, die koronare Herzkrankheit und tachykarde Herzrhythmusstörungen. Hinzu kommt, daß bei der Behandlung der Herzinsuffizienz die Verminderung der Mortalität unter Carvedilol, Bisoprolol und Metoprolol belegt ist.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 44.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 59.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • CIBIS II Study (1999): The cardiac insufficiency bisoprolol study II (CIBISII): a randomised trial. Lancet 353: 9–13.

    Article  Google Scholar 

  • Deutsche Liga zur Bekämpfung des hohen Blutdrucks/Deutsche Hypertonie Gesellschaft (2000): Empfehlungen zur Hochdruckbehandlung. http://www.paritaet.org/hochdruckliga.

    Google Scholar 

  • Eschenhagen T., Scholz H. (2001): Herzinsuffizienz. In: Lemmer B., Brune K. (Hrsg.): Pharmakotherapie - Klinische Pharmakologie, 11. Auflage, Urban & Fischer Verlag, München Jena, S. 222–239.

    Google Scholar 

  • Frishman W.H. (1996): Secondary prevention of myocardial infarction: the roles of ß-adrenergic blockers, calcium-channel blockers, angiotensin converting enzyme inhibitors, and aspirin. In: Willich S.N, Muller J.E. (eds.): Triggering of acute coronary syndromes. Kluwer Academic Publishers, Dordrecht, Boston, London, pp. 367–394.

    Chapter  Google Scholar 

  • Frishman W.H., Kostis J., Strom J., Hossler M., Ekayam U. et al. (1979): Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 6: A comparison of pindolol and propranolol in the treatment of patients with angina pectoris. The role of intrinsic sympathomimetic activity. Am. Heart J. 98: 526–535.

    Article  PubMed  CAS  Google Scholar 

  • Hoffman B.B., Lefkowitz R.J. (1996): Catecholamines, sympathomimetic drugs, and adrenergic receptor antagonists. In: Hardman J.G., Limbird L.E., Molinoff P.B., Ruddon R.W., Goodman Gilman A. (eds.): Goodman & Gilman’s The Pharmacological Basis of Therapeutics. McGraw-Hill, New York, 9th ed., pp. 232–248.

    Google Scholar 

  • Kilbinger H., Rahn K.-H. (2001): Hypertonie. In: Lemmer B., Brune K. (Hrsg.): Pharmakotherapie - Klinische Pharmakologie, 11. Auflage, Urban & Fischer Verlag, München Jena, S. 195–210.

    Google Scholar 

  • Ijzerman A.P., Soudijn W. (1989): The antiarrhythmic properties of ß-adrenoceptor antagonists. Trends Pharmacol. Sci. 10: 31–36.

    Article  PubMed  CAS  Google Scholar 

  • MERIT-HF Study (1999): Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL randomised intervention trial in congestive heart failure. Lancet 353: 2001–2007.

    Article  Google Scholar 

  • Packer M., Bristow M.R., Cohn J.N., Colucci W.S., Fowler M.B. et al. (1996): The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N. Engl. J. Med. 334:1349–1355.

    Article  PubMed  CAS  Google Scholar 

  • Palm D. (1987): Wie viele Beta-Rezeptoren-Blocker braucht der Arzt? Klin. Wochenschr. 65: 289–295.

    Article  PubMed  CAS  Google Scholar 

  • Poynard T., Calès P., Pasta L., Ideo G., Pascal J.-P. et al. and the Franco-Italian Multi-center Study Group (1991): Beta-adrenergic-antagonist drugs in the prevention of gastrointestinal bleeding in patients with cirrhosis and esophageal varices. N. Engl. J. Med. 324:1532–1538.

    Article  PubMed  CAS  Google Scholar 

  • Quyyumi A.A., Wright C, Mockus L., Fox K.M. (1984): Effect of partial agonist activity in ß-blockers in severe angina pectoris: A double blind comparison of pindolol and atenolol. Brit. Med. J. 289:951–953.

    Article  CAS  Google Scholar 

  • Schrör K., Kelm M. (2001): Koronare Herzkrankheit. In: Lemmer B., Brune K. (Hrsg.): Pharmakotherapie - Klinische Pharmakologie, 11. Auflage, Urban & Fischer Verlag, München Jena, S. 240–255.

    Google Scholar 

  • Van Nueten L., Taylor F.R., Robertson J.I. (1998): Nebivolol vs atenolol and placebo in essential hypertension: a double-blind randomised trial. J. Hum. Hypertens. 12: 135–140.

    Article  PubMed  Google Scholar 

  • WHO-ISH Guidelines Subcommittee (1999): 1999 World Health tension. Organization - International Society of Hypertension Guidelines for the Management of Hyper J. Hypertens. 17: 151–183.

    Google Scholar 

Download references

Authors
  1. Björn Lemmer
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Pharmakologisches Institut der Universität Heidelberg, Im Neuenheimer Feld 366, 69120, Heidelberg, Germany

    Ulrich Schwabe

  2. Bachstraße 29, 50858, Köln, Germany

    Dieter Paffrath

Rights and permissions

Reprints and permissions

Copyright information

© 2001 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Lemmer, B. (2001). Betarezeptorenblocker. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs-Report 2001. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-56434-5_18

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-56434-5_18

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-42079-8

  • Online ISBN: 978-3-642-56434-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation